ReviewMolecular neurobiology2025
Unveiling Exosomes and Microvesicles in Parkinson's Disease: Mechanistic Insights Into Cell Death Pathways and Therapeutic Potential.
Review in Molecular neurobiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Parkinson's disease (PD) is characterized by progressive neuronal loss driven by dysregulated cell death pathways, yet the precise role of extracellular vesicles (EVs) in mediating these processes remains fragmented. Exosomes, enriched with microRNAs (miRNAs) and proteins like α-synuclein, propagate pathology and modulate neuroprotection, while microvesicles, carrying cytokines, amplify neuroinflammation. We synthesize recent studies to critically analyze the mechanisms, such as the dual role of exosomal miRNAs in oxidative stress and neuroprotection, and address methodological limitations, including EV heterogeneity and model-specific discrepancies. By integrating recent findings on EV subpopulations, such as exosomes versus microvesicles, and their distinct roles in α-synuclein propagation, along with the interplay between neuroinflammation and pyroptosis via nucleotide-binding domain, leucine-rich repeat, and pyrin domain-containing 3 (NLRP3) inflammasome activation, this review proposes a mechanistic framework for harnessing EVs in PD therapeutics.
Indexed as
Identifiers
41298942What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.